25% of Employees, 46% of Hospitalisation Claims: Turning Screening Participation Into a Group Mediclaim Loss-Ratio Lever

Employee-benefit brokers have asserted for years that preventive screening lowers group mediclaim claims. The assertion rarely came with evidence an underwriter would accept. The third edition of the CII and MediBuddy report, Workplace Health Reimagined: India's Health AI Frontier, reported by Mint on 31 July 2026, changes that. Its central finding: employees who skip annual health check-ups face a hospitalisation rate of 7.27%, against 2.41% for those who screen annually. That is nearly a threefold difference in the probability of an inpatient event, the single most expensive category in any group health programme.

The concentration finding matters even more for pricing. The 25% of employees who completely avoid health check-ups account for 46% of all inpatient hospitalisation claims and 43% of total insurance payouts. A quarter of the covered lives is generating close to half of the claims outgo. For a corporate whose group mediclaim renewal is being loaded because of a poor claims ratio, this is not a wellness statistic. It is a map of where the loss ratio actually comes from.

The implication for a renewal negotiation is direct. If an employer can move even part of that non-participating quarter into annual screening and structured follow-up, the expected claim frequency of the worst-performing segment of the book falls. That is an argument about future burning cost, made with published data, and it belongs in the renewal discussion alongside the claims experience itself.

The same report explains why most corporate wellness spending has never shown up in the claims experience: 52% of employees take no action after receiving their health check-up results. The report attributes this to the absence of personalised guidance, reminders and prioritised referrals. A camp that screens 800 employees and then mails 800 PDF reports has identified risk without changing it. The hypertensive employee who never opens the report hospitalises at exactly the rate he would have without the camp.

The report's maturity analysis of 459 corporate benefits programmes found that 73% of organisations remain at the two lowest maturity stages, which it labels 'Break-Fix' and 'Benefit Listed'. In plain terms, roughly three in four Indian corporates either react to health events after they happen or list benefits that employees must discover and use on their own. At that maturity level, a screening camp is an expense line, not an intervention.

The cost of leaving health unmanaged extends beyond the mediclaim account. The report estimates that poor employee mental health costs Indian employers about Rs 1.1 trillion annually, with presenteeism contributing Rs 51,000 crore and absenteeism Rs 14,000 crore. Those losses never touch the insurance programme, but they sit in the same budget conversation, and they strengthen the case for funding follow-through rather than another one-day camp.

For screening to function as a loss-ratio lever, it has to be written into the arrangement with the insurer rather than run alongside it. In practice that means negotiating, at placement or renewal, a documented understanding that covers four elements:

1. A participation definition. What counts as screening: the test panel, the eligible population, whether spouse and parent lives are included, and the completion window within the policy year. Vague definitions produce disputed numbers at renewal.
2. A verification mechanism. Participation must be evidenced by the screening provider or TPA in aggregate form, not self-declared by HR. Insurers discount self-reported wellness data heavily, and they are right to.
3. A participation threshold with consequences. For example, a stated premium credit or a claims-experience adjustment at renewal if verified participation crosses an agreed percentage of covered employees, with the non-participating cohort's claims tracked separately.
4. A data protocol. What flows to the insurer (aggregate participation rates, cohort-level claims experience) and what never does (individual results). This is where the DPDP boundaries discussed below get documented.

Some insurers will resist committing numbers at placement. A workable fallback is a side letter or endorsement recording that verified participation data will be tabled at renewal and considered as a rating factor, with the format of that data agreed in advance. Even that weaker form changes the renewal dynamic, because the employer arrives with a dataset the insurer has pre-agreed to read. The broader context of group health premium hardening makes this preparation more valuable, not less: when every account is being loaded, the accounts that can evidence risk improvement are the ones that get differentiated treatment.

Brokers should be honest with clients about the difference between what insurers say in wellness marketing and what underwriters actually do at renewal.

What an underwriter will genuinely credit is evidence that changes expected claims cost: a verified participation rate trend across two or more policy years, cohort-level claims experience showing the screened population's hospitalisation frequency, and documentation that abnormal findings were followed up. This is the same logic as any other risk-improvement credit in commercial underwriting: the insurer pays for demonstrated change in the risk, not for activity.

What an insurer will only promise to consider is a single year of camp attendance, app downloads, step-challenge enrolment, or wellness-platform logins. None of these correlate with inpatient frequency in a way an actuary can use, and a promise to 'take wellness efforts into account' at renewal costs the insurer nothing.

The practical sequencing for a corporate starting from zero looks like this. Year one: baseline. Negotiate the participation definition and data protocol, run verified screening, accept that the credit this year may be nothing more than goodwill. Year two: bring participation data and the first cohort claims split to renewal, and push for an explicit adjustment. Year three onward: the dataset is now a rating input, and the employer can credibly resist a market-wide loading by showing its own book diverging from the market's claims trend. A screening programme is a multi-year premium strategy, and clients who expect a discount in month three should be told otherwise at the outset.

The report's 52% inaction figure is also a design specification, because it names the missing components: personalised guidance, reminders and prioritised referrals. A follow-through programme that changes claims outcomes has three working parts.

Personalised referral, not a generic report. Every abnormal result should convert into a specific next step: a named specialist consultation, a diagnostic follow-up, or an enrolment into a condition-management pathway. The employee should receive the action, the reason for it and the booking route, not a lab report to interpret alone. This is the single largest difference between screening that changes hospitalisation rates and screening that documents them.

A structured reminder cadence. One notification is not a programme. Employees with flagged results need a structured reminder sequence until the follow-up action is completed or explicitly declined, run by the screening provider or TPA rather than by the employer (for the access-control reasons covered in the next section). The cadence itself should be reported in aggregate: of the employees flagged, how many completed follow-up within 30, 60, 90 days.

Prioritised follow-up on the findings that matter most. Not all abnormal results carry equal claims consequence. A triage layer that prioritises the findings most associated with near-term hospitalisation, and concentrates outreach effort there, is what converts a screening dataset into a loss-ratio intervention. This is also where the follow-up numbers become renewal evidence: an employer who can show that the highest-risk decile of screened employees completed specialist follow-up at 70% is presenting an underwriter with a materially different risk from one who mailed reports.

Where claims data feeds back into this loop, the same discipline that governs group health claims analytics applies: the analysis runs on the insurer and TPA side, at cohort level, and the employer sees populations, not patients.

A screening-participation programme collects health data, which the Digital Personal Data Protection Act, 2023 treats as personal data processed under the Act's consent and purpose-limitation requirements. The programme design has to respect three boundaries, and the broker should insist they are documented before the first sample is drawn.

First, consent is individual and specific. An employee's consent to be screened is not consent for the employer to receive the results. The consent notice should state who receives individual results (the employee and the screening provider or TPA), what the employer receives (aggregate, de-identified participation and cohort statistics), and what the insurer receives. Enrolment in the group mediclaim policy does not substitute for this consent.

Second, the employer sees populations, never individuals. Participation rates by location or band, aggregate risk-category distributions, and cohort-level claims splits are legitimate employer-side reports. A named list of employees with abnormal findings is not, and an employer who receives one has acquired both a DPDP problem and an employment-law problem, since individual health data in managerial hands invites discrimination claims. Aggregation thresholds matter here: a 'cohort' of four employees in one branch is identification by another name.

Third, purpose limitation binds the insurer side too. Screening data shared for renewal rating should be used for that purpose, not repurposed into individual claims adjudication. The data protocol negotiated at placement should say so explicitly. The obligations of insurers, TPAs and intermediaries handling health data under the Act are covered in more depth in our post on the DPDP Act and insurance data privacy.

Pulled together, the renewal argument runs like this. The published evidence says the non-screening quarter of a workforce generates close to half of inpatient claims, and that screened employees hospitalise at roughly a third of the rate of unscreened ones. The employer has moved verified participation from its baseline to an agreed threshold, has follow-up completion data on flagged results, and can show the screened cohort's claims frequency. On that record, the corporate is asking the insurer to price the book it is becoming, not the book it was.

This argument also reframes the wellness budget conversation inside the client. Screening with follow-through is not an HR perk competing with the offsite; it is claims-cost management for a health insurance programme whose premium is being driven by a concentrated, addressable segment of the workforce. The Rs 1.1 trillion mental-health cost estimate in the same report makes the wider point: unmanaged employee health is already a cost line, whether or not it is measured.

For the broker, the work is contractual and evidential: define participation, verify it, split the claims experience, document follow-up, and police the DPDP boundaries that keep employees willing to participate. Sarvada gives commercial insurance brokers structured, searchable access to insurer policy wordings and the intelligence around them, so wellness credits, participation clauses and renewal commitments can be compared across the market on their actual drafted terms rather than on marketing claims. Request Access to build the renewal argument on evidence.